Where does Rexahn Pharmaceuticals, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Rexahn Pharmaceuticals, Inc. ranks #23,294 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Rexahn Pharmaceuticals, Inc. hold?

Rexahn Pharmaceuticals, Inc. holds 12 US utility patents granted between 2015 and 2020, spanning 8 technology areas.

What is Rexahn Pharmaceuticals, Inc.'s Innovation Score?

Rexahn Pharmaceuticals, Inc. has an Innovation Score of 30.4 out of 100 (34th percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Rexahn Pharmaceuticals, Inc. focus on?

Rexahn Pharmaceuticals, Inc.'s top technology area is C07D (Heterocyclic Compounds) with 9 patents, ranking #903 of 3,165 assignees active in that subclass. Grants appear in 8 CPC subclasses total.

Is Rexahn Pharmaceuticals, Inc.'s patent grant rate increasing or decreasing?

Rexahn Pharmaceuticals, Inc.'s recent grant velocity is -91% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Rexahn Pharmaceuticals, Inc.'s patents?

Rexahn Pharmaceuticals, Inc.'s patents average 19.2 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Rexahn Pharmaceuticals, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Rexahn Pharmaceuticals, Inc.

USPTO PatentsView assignee record - 12 granted patents across 8 technology areas, recorded in grant years 2015–2020. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07D (Heterocyclic Compounds).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Rexahn ranks #23,294 of 49,997 tracked US assignees by granted-patent volume, with 12 patents across 8 technology areas.

#23,294
of 49,997 US assignees by volume: 34th percentile
by Innovation Score (30.4/100): 19.2
avg claims per patent: -91%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R23294 · US Corporation #23,294 · 12 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-USCORP · VEL-DROP · BOOK-FULL

GRANTS-MICRO 12 grants
MID-PACK #23,294/49,997
PHOTO-FINISH Rentokil Initial 1927
CPC-NARROW C07D · 8 areas
INNOV-THIN 30.4/100
CLAIMS-RICH 19.2 claims/avg
TYPE-USCORP US Corporation
VEL-DROP -91% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Rentokil Initial 1927 PLC (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Rexahn’s 30.4 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 8.9 pts (29%) Velocity 0.0 pts (0%) Breadth 10.0 pts (33%) Claim depth 11.5 pts (38%)

Qualcomm Incorporated · highest

85
Rexahn Pharmaceuticals · this assignee

30
3D Lighting… · lowest

7

What this shows Rexahn's Innovation Score is 30.4/100 (34th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Rexahn?

Each dot is one of Rexahn’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Rexahn’s own 19.2 claims/patent is ABOVE the 17.3 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Rexahn vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Rexahn's grants concentrate

Rexahn Pharmaceuticals, Inc. is a focused PatentsView assignee: 8 CPC subclasses with 75% of grants classified under C07D (Heterocyclic Compounds). Peak complete grant year is 2017 (4 grants) versus a trough of 1 in 2016. By volume, Rexahn sits between Rentokil Initial 1927 PLC and RO Technologies, LLC.

Rentokil Initial…

12
Rescon

12
Resilient Power S…

12
Resuscitec

12
Rhodia Acetow

12
Riiid

12
Ring-

12
RO

12
Rexahn Pharmaceut… ◀

12

What this shows Rexahn holds 12 patents at rank #23,270, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Rexahn

By rank, the assignees closest to #23,270 in granted patent volume.

Leaders in C07D (Heterocyclic Compounds)

Other assignees with the most granted patents in Rexahn's primary technology class.

Rexahn's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

30 34th percentile higher than 34% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2020

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Rexahn Pharmaceuticals, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	2	16.7%
2016	1	8.3%
2017	4	33.3%
2018	3	25.0%
2019	1	8.3%
2020	1	8.3%

Which technologies does Rexahn Pharmaceuticals, Inc. patent most?

C07D - Heterocyclic Compounds 9

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 9

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 9

C07F - Acyclic, Carbocyclic OR Heterocyclic Compounds Containing Elements Other Than Carbon, Hydrogen, Halogen, Oxygen, Nitrogen, Sulfur, Selenium OR Tellurium 3

C12Y - Enzymes 2

C07K - Peptides 2

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 2

B82Y - Specific Uses OR Applications OF NANOSTRUCTURES; Measurement OR Analysis OF NANOSTRUCTURES; Manufacture OR Treatment OF Nanostructures 1

Top 8 of 8 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Rexahn Pharmaceuticals, Inc.'s patent record in context - here's where to go next.

Rexahn Pharmaceuticals, Inc.'s lead technology class is C07D (Heterocyclic Compounds), 75% of its portfolio - see every assignee active in that class. Explore C07D
Ranked #23,294 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Rexahn Pharmaceuticals, Inc. against Rentokil Initial 1927 PLC, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 30.4/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.